<!doctype html><html lang=en-us><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=generator content="Wowchemy 5.7.0 for Hugo"><link rel=stylesheet href=/css/vendor-bundle.min.16f785cdb553c8c4431db6775122af35.css media=print onload='this.media="all"'><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/academicons@1.9.2/css/academicons.min.css integrity="sha512-KlJCpRsLf+KKu2VQa5vmRuClRFjxc5lXO03ixZt82HZUk41+1I0bD8KBSA0fY290ayMfWYI9udIqeOWSu1/uZg==" crossorigin=anonymous media=print onload='this.media="all"'><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/leaflet@1.7.1/dist/leaflet.min.css integrity crossorigin=anonymous media=print onload='this.media="all"'><link rel=stylesheet href=/css/wowchemy.5928d6f6b5eee121dc6141d2cdd0af46.css><link rel=stylesheet href=/css/libs/chroma/github-light.min.css title=hl-light media=print onload='this.media="all"'><link rel=stylesheet href=/css/libs/chroma/dracula.min.css title=hl-dark media=print onload='this.media="all"' disabled><meta name=author content="Christian Brueffer"><meta name=description content="**Background**<br />
More than three-quarters of primary breast cancers are positive for estrogen receptor alpha (ER; encoded by the gene *ESR1*), the most important factor for directing anti-estrogenic endocrine therapy. Although mutation in *ESR1* is known as an acquired mechanism of resistance to endocrine therapy (ET), found in 12-55% of metastatic breast cancers treated previously with ET, the impact of *ESR1* mutation on therapy response in primary breast cancer is unclear.<br />
**Patients and Methods**<br />
In this study we analyzed 3217 real-world and population-based early-stage primary breast cancers (within the SCAN-B study, ClinicalTrials.gov NCT02306096). Tissues were sampled from initial diagnosis prior to any treatment and analyzed for the presence of ESR1 mutations using RNA sequencing. Mutations were verified by SAGAsafe droplet digital PCR.<br />
**Results**<br />
We identified *ESR1* resistance mutations in 30 cases (0.9%), of which 29 were ER-positive (1.1%). In ER-positive disease, presence of *ESR1* mutation was significantly associated to poor relapse-free survival (RFS) and overall survival (OS) (p=0.011 and p=0.019, respectively), and moreover predicted poor RFS and OS within the patient group that received ET (p=0.007 and p=0.010, respectively).<br />
**Conclusions**<br />
These results indicate that *ESR1* mutations at diagnosis of untreated primary breast cancer are rare, however we confirm for the first time that such early mutations predict eventual resistance to standard hormone therapy in the adjuvant setting. If replicated, tumor *ESR1* screening may be considered in ER-positive primary breast cancer and, in mutated cases, ER-degraders such as fulvestrant or other therapeutic options may be considered as more appropriate. "><link rel=alternate hreflang=en-us href=https://www.brueffer.io/publication/2020_aacr/><link rel=canonical href=https://www.brueffer.io/publication/2020_aacr/><link rel=manifest href=/manifest.webmanifest><link rel=icon type=image/png href=/media/icon_hu7422bdd1ad1d5b8840d6088d6ba7ed4c_15338_32x32_fill_lanczos_center_3.png><link rel=apple-touch-icon type=image/png href=/media/icon_hu7422bdd1ad1d5b8840d6088d6ba7ed4c_15338_180x180_fill_lanczos_center_3.png><meta name=theme-color content="#1565c0"><meta property="twitter:card" content="summary_large_image"><meta property="twitter:site" content="@cbrueffer"><meta property="twitter:creator" content="@cbrueffer"><meta property="twitter:image" content="https://www.brueffer.io/publication/2020_aacr/featured.png"><meta property="og:site_name" content="Christian Brueffer"><meta property="og:url" content="https://www.brueffer.io/publication/2020_aacr/"><meta property="og:title" content="Abstract CT074: Pre-existing ESR1 mutations in early-stage primary breast cancer predict failure of endocrine therapy and poor survival | Christian Brueffer"><meta property="og:description" content="**Background**<br />
More than three-quarters of primary breast cancers are positive for estrogen receptor alpha (ER; encoded by the gene *ESR1*), the most important factor for directing anti-estrogenic endocrine therapy. Although mutation in *ESR1* is known as an acquired mechanism of resistance to endocrine therapy (ET), found in 12-55% of metastatic breast cancers treated previously with ET, the impact of *ESR1* mutation on therapy response in primary breast cancer is unclear.<br />
**Patients and Methods**<br />
In this study we analyzed 3217 real-world and population-based early-stage primary breast cancers (within the SCAN-B study, ClinicalTrials.gov NCT02306096). Tissues were sampled from initial diagnosis prior to any treatment and analyzed for the presence of ESR1 mutations using RNA sequencing. Mutations were verified by SAGAsafe droplet digital PCR.<br />
**Results**<br />
We identified *ESR1* resistance mutations in 30 cases (0.9%), of which 29 were ER-positive (1.1%). In ER-positive disease, presence of *ESR1* mutation was significantly associated to poor relapse-free survival (RFS) and overall survival (OS) (p=0.011 and p=0.019, respectively), and moreover predicted poor RFS and OS within the patient group that received ET (p=0.007 and p=0.010, respectively).<br />
**Conclusions**<br />
These results indicate that *ESR1* mutations at diagnosis of untreated primary breast cancer are rare, however we confirm for the first time that such early mutations predict eventual resistance to standard hormone therapy in the adjuvant setting. If replicated, tumor *ESR1* screening may be considered in ER-positive primary breast cancer and, in mutated cases, ER-degraders such as fulvestrant or other therapeutic options may be considered as more appropriate. "><meta property="og:image" content="https://www.brueffer.io/publication/2020_aacr/featured.png"><meta property="og:locale" content="en-us"><meta property="article:published_time" content="2020-08-15T00:00:00+00:00"><meta property="article:modified_time" content="2020-08-15T00:00:00+00:00"><script type=application/ld+json>{"@context":"https://schema.org","@type":"Article","mainEntityOfPage":{"@type":"WebPage","@id":"https://www.brueffer.io/publication/2020_aacr/"},"headline":"Abstract CT074: Pre-existing ESR1 mutations in early-stage primary breast cancer predict failure of endocrine therapy and poor survival","image":["https://www.brueffer.io/publication/2020_aacr/featured.png"],"datePublished":"2020-08-15T00:00:00Z","dateModified":"2020-08-15T00:00:00Z","author":{"@type":"Person","name":"Malin Dahlgren"},"publisher":{"@type":"Organization","name":"Christian Brueffer","logo":{"@type":"ImageObject","url":"https://www.brueffer.io/media/icon_hu7422bdd1ad1d5b8840d6088d6ba7ed4c_15338_192x192_fill_lanczos_center_3.png"}},"description":"**Background**\u003cbr /\u003e\nMore than three-quarters of primary breast cancers are positive for estrogen receptor alpha (ER; encoded by the gene *ESR1*), the most important factor for directing anti-estrogenic endocrine therapy. Although mutation in *ESR1* is known as an acquired mechanism of resistance to endocrine therapy (ET), found in 12-55% of metastatic breast cancers treated previously with ET, the impact of *ESR1* mutation on therapy response in primary breast cancer is unclear.\u003cbr /\u003e\n**Patients and Methods**\u003cbr /\u003e\nIn this study we analyzed 3217 real-world and population-based early-stage primary breast cancers (within the SCAN-B study, ClinicalTrials.gov NCT02306096). Tissues were sampled from initial diagnosis prior to any treatment and analyzed for the presence of ESR1 mutations using RNA sequencing. Mutations were verified by SAGAsafe droplet digital PCR.\u003cbr /\u003e\n**Results**\u003cbr /\u003e\nWe identified *ESR1* resistance mutations in 30 cases (0.9%), of which 29 were ER-positive (1.1%). In ER-positive disease, presence of *ESR1* mutation was significantly associated to poor relapse-free survival (RFS) and overall survival (OS) (p=0.011 and p=0.019, respectively), and moreover predicted poor RFS and OS within the patient group that received ET (p=0.007 and p=0.010, respectively).\u003cbr /\u003e\n**Conclusions**\u003cbr /\u003e\nThese results indicate that *ESR1* mutations at diagnosis of untreated primary breast cancer are rare, however we confirm for the first time that such early mutations predict eventual resistance to standard hormone therapy in the adjuvant setting. If replicated, tumor *ESR1* screening may be considered in ER-positive primary breast cancer and, in mutated cases, ER-degraders such as fulvestrant or other therapeutic options may be considered as more appropriate. "}</script><title>Abstract CT074: Pre-existing ESR1 mutations in early-stage primary breast cancer predict failure of endocrine therapy and poor survival | Christian Brueffer</title></head><body id=top data-spy=scroll data-offset=70 data-target=#TableOfContents class=page-wrapper data-wc-page-id=b914e4f5c3bf04bbe604109099d9ebb8><script src=/js/wowchemy-init.min.ec9d49ca50e4b80bdb08f0417a28ed84.js></script><aside class=search-modal id=search><div class=container><section class=search-header><div class="row no-gutters justify-content-between mb-3"><div class=col-6><h1>Search</h1></div><div class="col-6 col-search-close"><a class=js-search href=# aria-label=Close><i class="fas fa-times-circle text-muted" aria-hidden=true></i></a></div></div><div id=search-box><input name=q id=search-query placeholder=Search... autocapitalize=off autocomplete=off autocorrect=off spellcheck=false type=search class=form-control aria-label=Search...></div></section><section class=section-search-results><div id=search-hits></div></section></div></aside><div class="page-header header--fixed"><header><nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id=navbar-main><div class=container-xl><div class="d-none d-lg-inline-flex"><a class=navbar-brand href=/>Christian Brueffer</a></div><button type=button class=navbar-toggler data-toggle=collapse data-target=#navbar-content aria-controls=navbar-content aria-expanded=false aria-label="Toggle navigation">
<span><i class="fas fa-bars"></i></span></button><div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none"><a class=navbar-brand href=/>Christian Brueffer</a></div><div class="navbar-collapse main-menu-item collapse justify-content-start" id=navbar-content><ul class="navbar-nav d-md-inline-flex"><li class=nav-item><a class=nav-link href=/><span>About Me</span></a></li><li class=nav-item><a class=nav-link href=/#consulting><span>Consulting</span></a></li><li class=nav-item><a class=nav-link href=/#posts><span>Posts</span></a></li><li class=nav-item><a class=nav-link href=/#projects><span>Projects</span></a></li><li class=nav-item><a class=nav-link href=/event/><span>Talks</span></a></li><li class="nav-item dropdown"><a href=# class="nav-link dropdown-toggle" data-toggle=dropdown aria-haspopup=true><span>Research</span><span class=caret></span></a><div class=dropdown-menu><a class=dropdown-item href=/#tags><span>Popular Topics</span></a>
<a class=dropdown-item href=/#featured><span>Featured Publications</span></a>
<a class=dropdown-item href=/#publications><span>Recent Publications</span></a>
<a class=dropdown-item href=/publication/><span>All Publications</span></a></div></li><li class=nav-item><a class=nav-link href=/#contact><span>Contact</span></a></li></ul></div><ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2"><li class=nav-item><a class="nav-link js-search" href=# aria-label=Search><i class="fas fa-search" aria-hidden=true></i></a></li><li class="nav-item dropdown theme-dropdown"><a href=# class=nav-link data-toggle=dropdown aria-haspopup=true aria-label="Display preferences"><i class="fas fa-moon" aria-hidden=true></i></a><div class=dropdown-menu><a href=# class="dropdown-item js-set-theme-light"><span>Light</span></a>
<a href=# class="dropdown-item js-set-theme-dark"><span>Dark</span></a>
<a href=# class="dropdown-item js-set-theme-auto"><span>Automatic</span></a></div></li></ul></div></nav></header></div><div class=page-body><div class=pub><div class="article-container pt-3"><h1>Abstract CT074: Pre-existing ESR1 mutations in early-stage primary breast cancer predict failure of endocrine therapy and poor survival</h1><div class=article-metadata><div><span>Malin Dahlgren</span>, <span>Anthony M. George</span>, <span class=author-highlighted>Christian Brueffer</span>, <span>Sergii Gladchuk</span>, <span>Yilun Chen</span>, <span>Johan Vallon-Christersson</span>, <span>Cecilia Hegardt</span>, <span>Jari Häkkinen</span>, <span>Lisa Rydén</span>, <span>Martin Malmberg</span>, <span>Christer Larsson</span>, <span>Sofia K. Gruvberger-Saal</span>, <span>Anna Ehinger</span>, <span>Niklas Loman</span>, <span>Åke Borg</span>, <span>Lao H. Saal</span></div><span class=article-date>August, 2020</span></div><div class="btn-links mb-3"><a class="btn btn-outline-primary btn-page-header" href=https://doi.org/10.1158/1538-7445.AM2020-CT074 target=_blank rel=noopener>DOI</a></div></div><div class="article-header article-container featured-image-wrapper mt-4 mb-4" style=max-width:520px;max-height:696px><div style=position:relative><img src=/publication/2020_aacr/featured_huc0bb50f6c84ddd9e22d2f361d2cacc5b_624852_720x2500_fit_q75_h2_lanczos_3.webp width=520 height=696 alt class=featured-image></div></div><div class=article-container><h3>Abstract</h3><p class=pub-abstract><strong>Background</strong><br>More than three-quarters of primary breast cancers are positive for estrogen receptor alpha (ER; encoded by the gene <em>ESR1</em>), the most important factor for directing anti-estrogenic endocrine therapy. Although mutation in <em>ESR1</em> is known as an acquired mechanism of resistance to endocrine therapy (ET), found in 12-55% of metastatic breast cancers treated previously with ET, the impact of <em>ESR1</em> mutation on therapy response in primary breast cancer is unclear.<br><strong>Patients and Methods</strong><br>In this study we analyzed 3217 real-world and population-based early-stage primary breast cancers (within the SCAN-B study, ClinicalTrials.gov NCT02306096). Tissues were sampled from initial diagnosis prior to any treatment and analyzed for the presence of ESR1 mutations using RNA sequencing. Mutations were verified by SAGAsafe droplet digital PCR.<br><strong>Results</strong><br>We identified <em>ESR1</em> resistance mutations in 30 cases (0.9%), of which 29 were ER-positive (1.1%). In ER-positive disease, presence of <em>ESR1</em> mutation was significantly associated to poor relapse-free survival (RFS) and overall survival (OS) (p=0.011 and p=0.019, respectively), and moreover predicted poor RFS and OS within the patient group that received ET (p=0.007 and p=0.010, respectively).<br><strong>Conclusions</strong><br>These results indicate that <em>ESR1</em> mutations at diagnosis of untreated primary breast cancer are rare, however we confirm for the first time that such early mutations predict eventual resistance to standard hormone therapy in the adjuvant setting. If replicated, tumor <em>ESR1</em> screening may be considered in ER-positive primary breast cancer and, in mutated cases, ER-degraders such as fulvestrant or other therapeutic options may be considered as more appropriate.</p><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Type</div><div class="col-12 col-md-9"><a href=/publication/#1>Conference paper</a></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Publication</div><div class="col-12 col-md-9"><em>Cancer Research, 2020. 80:16_Supplement</em></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=space-below></div><div class=article-style><html><style>section{background:#fff;color:#000;border-radius:1em;padding:1em;left:50%}#inner{display:inline-block;display:flex;align-items:center;justify-content:center}</style><section><div id=inner><script type=text/javascript src=https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js></script>
<span style=float:left ; class=__dimensions_badge_embed__ data-doi=10.1158/1538-7445.AM2020-CT074 data-hide-zero-citations=true data-legend=always></span><script async src=https://badge.dimensions.ai/badge.js></script><div style=float:right ; data-link-target=_blank data-badge-details=right data-badge-type=medium-donut data-doi=10.1158/1538-7445.AM2020-CT074 data-condensed=true data-hide-no-mentions=true class=altmetric-embed></div></div></section></div><div class=article-tags><a class="badge badge-light" href=/tag/cancer/>Cancer</a>
<a class="badge badge-light" href=/tag/breast-cancer/>Breast Cancer</a>
<a class="badge badge-light" href=/tag/scan-b/>SCAN-B</a>
<a class="badge badge-light" href=/tag/rna-sequencing/>RNA Sequencing</a>
<a class="badge badge-light" href=/tag/digital-pcr/>Digital PCR</a>
<a class="badge badge-light" href=/tag/bioinformatics/>Bioinformatics</a></div><div class=share-box><ul class=share><li><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.brueffer.io%2Fpublication%2F2020_aacr%2F&text=Abstract+CT074%3A+Pre-existing+ESR1+mutations+in+early-stage+primary+breast+cancer+predict+failure+of+endocrine+therapy+and+poor+survival" target=_blank rel=noopener class=share-btn-twitter aria-label=twitter><i class="fab fa-twitter"></i></a></li><li><a href="https://www.facebook.com/sharer.php?u=https%3A%2F%2Fwww.brueffer.io%2Fpublication%2F2020_aacr%2F&t=Abstract+CT074%3A+Pre-existing+ESR1+mutations+in+early-stage+primary+breast+cancer+predict+failure+of+endocrine+therapy+and+poor+survival" target=_blank rel=noopener class=share-btn-facebook aria-label=facebook><i class="fab fa-facebook"></i></a></li><li><a href="mailto:?subject=Abstract%20CT074%3A%20Pre-existing%20ESR1%20mutations%20in%20early-stage%20primary%20breast%20cancer%20predict%20failure%20of%20endocrine%20therapy%20and%20poor%20survival&body=https%3A%2F%2Fwww.brueffer.io%2Fpublication%2F2020_aacr%2F" target=_blank rel=noopener class=share-btn-email aria-label=envelope><i class="fas fa-envelope"></i></a></li><li><a href="https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fwww.brueffer.io%2Fpublication%2F2020_aacr%2F&title=Abstract+CT074%3A+Pre-existing+ESR1+mutations+in+early-stage+primary+breast+cancer+predict+failure+of+endocrine+therapy+and+poor+survival" target=_blank rel=noopener class=share-btn-linkedin aria-label=linkedin-in><i class="fab fa-linkedin-in"></i></a></li><li><a href="https://web.whatsapp.com/send?text=Abstract+CT074%3A+Pre-existing+ESR1+mutations+in+early-stage+primary+breast+cancer+predict+failure+of+endocrine+therapy+and+poor+survival%20https%3A%2F%2Fwww.brueffer.io%2Fpublication%2F2020_aacr%2F" target=_blank rel=noopener class=share-btn-whatsapp aria-label=whatsapp><i class="fab fa-whatsapp"></i></a></li><li><a href="https://service.weibo.com/share/share.php?url=https%3A%2F%2Fwww.brueffer.io%2Fpublication%2F2020_aacr%2F&title=Abstract+CT074%3A+Pre-existing+ESR1+mutations+in+early-stage+primary+breast+cancer+predict+failure+of+endocrine+therapy+and+poor+survival" target=_blank rel=noopener class=share-btn-weibo aria-label=weibo><i class="fab fa-weibo"></i></a></li></ul></div><div class="media author-card content-widget-hr"><a href=https://www.brueffer.io><img class="avatar mr-3 avatar-circle" src=/authors/cbrueffer/avatar_hu17f80c4ec327e7baf25f17a8159016b3_537581_270x270_fill_lanczos_center_3.png alt="Christian Brueffer"></a><div class=media-body><h5 class=card-title><a href=https://www.brueffer.io>Christian Brueffer</a></h5><h6 class=card-subtitle>Bioinformatician and Data Scientist</h6><p class=card-text>Freelance Bioinformatician and Data Scientist with interests including disease biology and diagnostics, particularly in cancer, and open source bioinformatics.</p><ul class=network-icon aria-hidden=true><li><a href=mailto:christian@brueffer.io><i class="fas fa-envelope"></i></a></li><li><a href=https://twitter.com/cbrueffer target=_blank rel=noopener><i class="fab fa-twitter"></i></a></li><li><a href=https://mastodon.social/@cbrueffer target=_blank rel=noopener><i class="fab fa-mastodon"></i></a></li><li><a href=https://www.linkedin.com/in/cbrueffer target=_blank rel=noopener><i class="fab fa-linkedin"></i></a></li><li><a href="https://scholar.google.com/citations?user=BFnR7W8AAAAJ" target=_blank rel=noopener><i class="ai ai-google-scholar"></i></a></li><li><a href=https://www.researchgate.net/profile/Christian_Brueffer2 target=_blank rel=noopener><i class="ai ai-researchgate"></i></a></li><li><a href=https://orcid.org/0000-0002-3826-0989 target=_blank rel=noopener><i class="ai ai-orcid"></i></a></li><li><a href=https://github.com/cbrueffer target=_blank rel=noopener><i class="fab fa-github"></i></a></li></ul></div></div></div></div></div><div class=page-footer><div class=container><footer class=site-footer><p class="powered-by copyright-license-text">© 2023 Christian Brueffer. This work is licensed under <a href=https://creativecommons.org/licenses/by-nc-nd/4.0 rel="noopener noreferrer" target=_blank>CC BY NC ND 4.0</a></p><p class="powered-by footer-license-icons"><a href=https://creativecommons.org/licenses/by-nc-nd/4.0 rel="noopener noreferrer" target=_blank aria-label="Creative Commons"><i class="fab fa-creative-commons fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-by fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-nc fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-nd fa-2x" aria-hidden=true></i></a></p><p class=powered-by>Published with <a href="https://wowchemy.com/?utm_campaign=poweredby" target=_blank rel=noopener>Wowchemy</a> — the free, <a href=https://github.com/wowchemy/wowchemy-hugo-themes target=_blank rel=noopener>open source</a> website builder that empowers creators.</p></footer></div></div><script src=/js/vendor-bundle.min.46271ef31da3f018e9cd1b59300aa265.js></script>
<script src=https://cdn.jsdelivr.net/npm/leaflet@1.7.1/dist/leaflet.min.js integrity crossorigin=anonymous></script>
<script id=search-hit-fuse-template type=text/x-template>
    <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
    </div>
  </script><script src=https://cdn.jsdelivr.net/gh/krisk/Fuse@v3.2.1/dist/fuse.min.js integrity="sha512-o38bmzBGX+hD3JHWUFCDA09btWaqrNmoJ3RXLlrysA7PP01Kgs4UlE4MhelE1v5dJR3+cxlR4qQlotsW7jKsnw==" crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/gh/julmot/mark.js@8.11.1/dist/jquery.mark.min.js integrity="sha512-mhbv5DqBMgrWL+32MmsDOt/OAvqr/cHimk6B8y/bx/xS88MVkYGPiVv2ixKVrkywF2qHplNRUvFsAHUdxZ3Krg==" crossorigin=anonymous></script>
<script id=page-data type=application/json>{"use_headroom":true}</script><script src=/js/wowchemy-headroom.db4755770454eb63685f8de785c0a172.js type=module></script>
<script src=/en/js/wowchemy.min.8621d706896ab6d11dd8fd7042e20931.js></script>
<script src=/js/wowchemy-map.a26e9d2f7238ba5b868384f1c5bc6477.js type=module></script><div id=modal class="modal fade" role=dialog><div class=modal-dialog><div class=modal-content><div class=modal-header><h5 class=modal-title>Cite</h5><button type=button class=close data-dismiss=modal aria-label=Close>
<span aria-hidden=true>&#215;</span></button></div><div class=modal-body><pre><code></code></pre></div><div class=modal-footer><a class="btn btn-outline-primary my-1 js-copy-cite" href=# target=_blank><i class="fas fa-copy"></i> Copy</a>
<a class="btn btn-outline-primary my-1 js-download-cite" href=# target=_blank><i class="fas fa-download"></i> Download</a><div id=modal-error></div></div></div></div></div><script src=/js/wowchemy-publication.68f8d7090562ca65fc6d3cb3f8f2d2cb.js type=module></script>
<script type=text/javascript src=https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js></script>
<script async src=https://badge.dimensions.ai/badge.js></script></body></html>